JP2024539952A5 - - Google Patents

Info

Publication number
JP2024539952A5
JP2024539952A5 JP2024524610A JP2024524610A JP2024539952A5 JP 2024539952 A5 JP2024539952 A5 JP 2024539952A5 JP 2024524610 A JP2024524610 A JP 2024524610A JP 2024524610 A JP2024524610 A JP 2024524610A JP 2024539952 A5 JP2024539952 A5 JP 2024539952A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weeks
dota
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539952A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060331 external-priority patent/WO2023073603A1/en
Publication of JP2024539952A publication Critical patent/JP2024539952A/ja
Publication of JP2024539952A5 publication Critical patent/JP2024539952A5/ja
Pending legal-status Critical Current

Links

JP2024524610A 2021-10-27 2022-10-27 放射性核種錯体の組み合わせ療法 Pending JP2024539952A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272447P 2021-10-27 2021-10-27
US63/272,447 2021-10-27
PCT/IB2022/060331 WO2023073603A1 (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Publications (2)

Publication Number Publication Date
JP2024539952A JP2024539952A (ja) 2024-10-31
JP2024539952A5 true JP2024539952A5 (enExample) 2025-11-04

Family

ID=84365353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524610A Pending JP2024539952A (ja) 2021-10-27 2022-10-27 放射性核種錯体の組み合わせ療法

Country Status (11)

Country Link
US (1) US20250387523A1 (enExample)
EP (1) EP4422701A1 (enExample)
JP (1) JP2024539952A (enExample)
KR (1) KR20240093832A (enExample)
CN (1) CN118159304A (enExample)
AU (1) AU2022374887A1 (enExample)
CA (1) CA3234495A1 (enExample)
IL (1) IL312106A (enExample)
MX (1) MX2024004961A (enExample)
TW (1) TW202332473A (enExample)
WO (1) WO2023073603A1 (enExample)

Similar Documents

Publication Publication Date Title
Kwekkeboom et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake
Breeman et al. The addition of DTPA to [177Lu-DOTA0, Tyr3] octreotate prior to administration reduces rat skeleton uptake of radioactivity
RU2160121C2 (ru) Агенты для лучевой терапии, содержащие олово-117m
JP2022532187A5 (enExample)
Picco et al. Primary hypothyroidism as a consequence of 131‐I‐metaiodobenzylguanidine treatment for children with neuroblastoma
Gao et al. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy
US6685913B1 (en) Lipid soluble radioactive metal chelates for tumor therapy
Khettery et al. Effect of pentagastrin, histalog, glucagon, secretin, and perchlorate on the gastric handling of 99mTc pertechnetate in mice
Giammarile et al. Bone pain palliation with 85Sr therapy
Pujol et al. Metastatic phaeochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy
AT405906B (de) Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
JP2023522983A (ja) 前立腺がんの診断および処置のための組成物、キットおよび方法
RU2024113993A (ru) Комбинированная терапия на основе радионуклидного комплекса
Bushnell et al. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher™) in patients with diffuse somatostatin receptor positive liver metastases
Kao et al. Quick diagnosis of hyperthyroidism with semiquantitative 30-minute technetium-99m-methoxy-isobutyl-isonitrile thyroid uptake
Van Soesbergen et al. Radiosynoviorthesis of the knee: a doubleblind trial of 1 versus 5 mCi Gold-198
JP2016532652A (ja) 高純度治療用骨剤
RU2025124374A (ru) Способы лечения глиобластомы
Changlai et al. Biodistribution and Dosimetry of 131I in Thyroidectomy Patients Using Semiquantitative γ-Camera Imaging
Kostial et al. Efficiency of a composite treatment for mixed fission products in rats
Lin et al. Reducing renal uptake of111In-DOTATOC: A comparison among various basic amino acids
Rajić An overview of Regional training course on therapeutic nuclear medicine
Kaltsas et al. Treatment of advanced neuroendocrine tumours with the radiolabelled somatostatin analogue octreotide
KR20240093832A (ko) 방사성 핵종 복합체의 조합 요법
JP7792746B2 (ja) 治療用骨剤の使用方法